J. Larkin describes key molecular pathways in melanoma, focussing on RAS-RAF-MEK-ERK. He describes NRAS-driven and other molecularly defined subgroups, MEK as a therapeutic target, data with MEK inhibitors including combinations with BRAFi, and early data in uveal melanoma.
Inhibition of MEK to Treat Cancer: Focus on Melanoma